Advertisement

Picture BIO Deutschland German Corona Special 2021 Digital 650x80px
Organisation › Details

Bicycle Therapeutics plc (Nasdaq: BCYC)

Bicycle Therapeutics (NASDAQ: BCYC) is a clinical-stage biopharmaceutical company developing a novel class of medicines, referred to as Bicycles®, for diseases that are underserved by existing therapeutics. Bicycles are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity, making Bicycles attractive candidates for drug development. Bicycle’s lead product candidate, BT1718, is a Bicycle Toxin Conjugate being investigated in an ongoing Phase I/IIa clinical trial in collaboration with the Centre for Drug Development of Cancer Research UK. Bicycle is headquartered in Cambridge, U.K. with many key functions and members of its leadership team located in Lexington, MA. *

 

Period Start 2019-08-08 reorganised before
  Group Bicycle Therapeutics (Group)
  Predecessor Bicycle Therapeutics Ltd.
Products Industry Bicycle Drug Conjugates®
  Industry 2 phage display technology
Persons Person Lee, Kevin (Bicycle Therapeutics 201509– CEO before Pfizer + GSK)
  Person 2 Winter, Gregory (MRC + CAT + Domantis)
     
Region Region Babraham, Cambridgeshire
  Country United Kingdom (GB)
  City CB22 3AT Cambridge
    Address record changed: 2020-12-02
     
Basic data Employees n. a.
     
    * Document for �About Section�: Bicycle Therapeutics plc. (8/8/19). "Press Release: Bicycle Therapeutics Reports Second Quarter 2019 Financial Results and Provides Clinical Update". Cambridge & Boston, MA.
     
   
Record changed: 2020-08-04

Advertisement

Picture EBD Group Global Partnering Four Events One Price 650x80

More documents for Bicycle Therapeutics (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture [iito] Back into Ad 650x80px




» top